Scottsdale, AZ, United States of America

Paul Gonzales

This inventor holds 3 USPTO granted patents and 3 EPO patents. Top assignee: Translational Drug Development, LLC. Active years: 2020-2024.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Paul Gonzales: Innovator in Pharmaceutical Compositions

Introduction

Paul Gonzales is a notable inventor based in Scottsdale, AZ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions aimed at treating cancer. With a total of 3 patents to his name, Gonzales continues to push the boundaries of medical innovation.

Latest Patents

Gonzales's latest patents include groundbreaking work on benzamide and active compound compositions. One of his inventions describes pharmaceutical compositions that comprise a PD-1 axis binding antagonist, a CTLA4 antagonist, a DNA demethylating agent, and a benzamide compound. These compositions are designed for use in treating cancer, particularly in enhancing tumor immunogenicity. Another patent focuses on similar compositions, emphasizing methods for treating conditions where enhanced immunogenicity is desired.

Career Highlights

Paul Gonzales is currently associated with Translational Drug Development, LLC, where he applies his expertise in pharmaceutical innovation. His work is pivotal in developing new treatment methodologies that can significantly impact cancer therapy.

Collaborations

Gonzales collaborates with esteemed colleagues such as Tong Wang and Stephen Gately, contributing to a dynamic research environment that fosters innovation in drug development.

Conclusion

Paul Gonzales stands out as a key figure in the pharmaceutical industry, with his innovative patents paving the way for advancements in cancer treatment. His dedication to enhancing therapeutic options reflects his commitment to improving patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…